Monthly file
October 2026
Every report in the October 2026 file of The Peptide Gazette: 9 reports built on primary documents dated that month. A report is filed under the date of the document it stands on, never the date the page was generated.
-
FDA asks consumer organisations to nominate advisory committee representatives
The agency requested that consumer organisations interested in selecting consumer representatives notify it in writing, and asked for nominations to fill current and expected vacancies.
-
Survodutide liver fibrosis record updated as recruiting
The Phase 3 LIVERAGE entry, sponsored by Boehringer Ingelheim, was last updated on 1 October 2026.
-
Boehringer Ingelheim posts a survodutide record as not yet recruiting
The Phase 3 SYNCHRONIZE-START entry was last updated on 2 October 2026 and has not opened to enrolment.
-
Novo Nordisk cagrilintide record moves to active, not recruiting
The Phase 3 entry covering adults living with overweight or obesity and type 2 diabetes was last updated on 7 October 2026.
-
Lilly multi-agent liver disease record opens for recruitment
The Phase 3 SYNERGY-Outcomes entry covering adults with metabolic dysfunction-associated steatotic liver disease was updated on 8 October 2026.
-
Retatrutide outcomes record moves to active, not recruiting
The Phase 3 TRIUMPH-Outcomes entry, sponsored by Eli Lilly and Company, was last updated on 8 October 2026.
-
BrightGene updates two BGM0504 registry records on one day
A Phase 2 entry is now marked completed and a Phase 3 entry registered in Indonesia is marked active, not recruiting. Both were updated on 13 October 2026.
-
Sheba Medical Center marks a Phase 2 healthy ageing record completed
The ELITE entry, returned by the registry among records matching semaglutide, was last updated on 13 October 2026.
-
Lilly paediatric tirzepatide registry record updated as recruiting
The Phase 3 entry covering participants aged 6 to under 12 was last updated on 13 October 2026 and carries the status recruiting.